Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Evotec has signed an agreement with Takeda Cambridge for identifying small molecules against GPCR and Protease targets involved in various CNS and Metabolic diseases.
Subscribe to our email newsletter
Under the contract, Evotec is expected to use its Screening Platform and proprietary GPCR modeling software for identifying and validating novel modulators against various targets selected by Takeda Cambridge.
Evotec chief operating officer Mario Polywka said they are proud to be selected by Takeda Cambridge to collaborate on this important project.
"We have invested significantly in our hit-identification platform and this alliance further validates the strength of this platform and Evotec’s ability to bring value to its partner’s drug discovery efforts," Polywka said.